Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H9O5.Na |
Molecular Weight | 280.208 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OC1=CC=CC=C1C(=O)OC2=CC=CC=C2C([O-])=O
InChI
InChIKey=JOCPDKGMOXSKRO-UHFFFAOYSA-M
InChI=1S/C14H10O5.Na/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17;/h1-8,15H,(H,16,17);/q;+1/p-1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C14H9O5 |
Molecular Weight | 257.2183 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/pro/salsalate.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23817699 |
https://www.ncbi.nlm.nih.gov/pubmed/6520777
Sources: https://www.drugs.com/pro/salsalate.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/23817699 |
https://www.ncbi.nlm.nih.gov/pubmed/6520777
Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001516 Sources: Salsalate selectively inhibits prostaglandin synthesis in vivo |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | DISALCID Approved UseSalsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, and related rheumatic disorder. |
|||
Palliative | DISALCID Approved UseSalsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Salicylic acid-induced inactivation of creatine kinase in the presence of lactoperoxidase and H2O2. | 2005 Jan 15 |
|
Phenolic compounds, sodium salicylate and related compounds, as inhibitors of tumor cell growth and inducers of apoptosis in mouse leukemia L1210 cells. | 2005 Jan-Feb |
|
siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. | 2008 Aug |
|
Salsalate improves glycemia and inflammatory parameters in obese young adults. | 2008 Feb |
|
A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women. | 2009 Jan |
|
Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. | 2009 Oct |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Apocynin improves insulin resistance through suppressing inflammation in high-fat diet-induced obese mice. | 2010 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Potential role of salicylates in type 2 diabetes. | 2010 Jul-Aug |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/salsalate.html
The usual dosage is 3000 mg daily, given in divided doses as follows: 1(two doses of two 750 mg tablets; 2) two doses of three 500 mg tablets; or 3) three doses of two 500 mg tablets.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:11:44 GMT 2023
by
admin
on
Sat Dec 16 11:11:44 GMT 2023
|
Record UNII |
06SH0H2G8M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
06SH0H2G8M
Created by
admin on Sat Dec 16 11:11:45 GMT 2023 , Edited by admin on Sat Dec 16 11:11:45 GMT 2023
|
PRIMARY | |||
|
23662396
Created by
admin on Sat Dec 16 11:11:45 GMT 2023 , Edited by admin on Sat Dec 16 11:11:45 GMT 2023
|
PRIMARY | |||
|
DTXSID40178111
Created by
admin on Sat Dec 16 11:11:45 GMT 2023 , Edited by admin on Sat Dec 16 11:11:45 GMT 2023
|
PRIMARY | |||
|
23520-54-9
Created by
admin on Sat Dec 16 11:11:45 GMT 2023 , Edited by admin on Sat Dec 16 11:11:45 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |